Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(13)70380-2
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 1, 2013
Authors
Publisher
Elsevier BV